Published: February 21, 2006
GCPSiro (USA) and SIRO Clinpharm (India) Announce Global Expansion to Deliver Comprehensive Clinical Trial Services to US Pharma and Biotechs
Siro Clinpharm Pvt. Ltd.
announced today the next step in the global expansion of its CRO business.
Siro Clinpharm has entered into a formal agreement with GCPSiro to offer a
US Clinical Research Organization specializing in the management of
late-stage clinical studies using proven capabilities in India.
Conducting clinical trials in India offers a number of advantages,
including a relatively lower trial cost per patient compared to the US and
Europe, access to an extensive pool of patients in a range of therapeutic
areas, knowledgeable investigators, and above all the ability to accelerate
patient enrollment.
Dr. Mark Bradshaw, Ph.D., President of GCPSiro, commented: "India offers a
widely accepted and compelling solution to pharma's urgent need to reduce
clinical trial recruitment time and overall R&D costs. US pharmaceutical
and biotech companies without an Indian presence have not had effective
access to these capabilities. GCPSiro, with offices in Princeton, NJ, and
San Jose, CA, now offers US-based pharmaceutical and biotech companies
immediate, managed access to the best and most established global clinical
trial capabilities in India. Pharma and biotech companies can now utilize
Indian clinical trial investigators, patient populations, and other expert
resources for their global registration trials without adding overheads or
internal project management costs. GCPSiro provides the necessary US-based
project management, client liaison and other direct drug development
support services."
Dr. Gautam Daftary, M.D., founder of Siro Clinpharm, commented: "The
highest level of scientific integrity, world-class quality, and a focus on
client service are the cornerstones of Siro and GCPSiro. Led by a senior
US pharmaceutical executive with significant first-hand experienced in
India, GCPSiro guarantees compliance with the principles of Good Clinical
Practice (GCP) and full US and India regulatory requirements."
GCPSiro has also established a group of top level US and European partner
companies and consultants to offer coordination of full clinical
development consulting and operational services to clients who need a
broader level of support. Services include US regulatory consulting,
clinical trial management and monitoring, data and statistical services,
and full US and European regulatory submission capabilities. For more
information on GCPSiro, visit www.gcpsiro.com.
About SIRO Clinpharm
SIRO Clinpharm Pvt. Ltd. is a leading full-service contract Clinical
Research Organization (CRO) providing clinical development solutions to
support Phase I - IV clinical trials in India. Armed with strong clinical
project management, data management and biometrics capabilities, SIRO is
successfully managing contracts for some of the leading global
pharmaceutical companies. SIRO has a 10-year track record delivering
pivotal data that has led to numerous FDA and EU approvals. In October
2005, SIRO was selected from among 60 companies as the 2005 winner of
Proximare's "Best Indian CRO Award" in Clinical Research (Phase I - IV).
For more information on SIRO Clinpharm, visit www.siroindia.com.
Distributed by Market Wire
Copyright © 2012, MarketWire
Copyright © 2012, NewsBlaze,
Daily News